Navigation Links
Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Date:7/1/2008

FRANKLIN, Mass., July 1 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE) announced today that it has initiated a clinical study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System (tCGM System) in patients with Type 1 and Type 2 diabetes. The Company expects to complete and announce the results of the study in the third quarter of 2008. Echo's non-invasive Symphony tCGM System consists of its Prelude(TM) SkinPrep System, which incorporates patented and leading-edge skin permeation control technology, and wireless transmission and proprietary transdermal biosensor technologies. Echo's Symphony tCGM System is designed to provide both diabetes and hospital patients with a reliable, needle-free, easy-to-use, affordable and comfortable-to-wear continuous glucose monitoring device.

"Building on the momentum generated from our prior four positive pilot clinical studies, we are excited to have started our next pilot study in the important diabetes home use market. Our new Prelude Skin Prep System is a competitively unique component of our Symphony tCGM System, enabling our system to generate painless, needle-free, continuous glucose measurements. The primary purpose of this new study is to evaluate the performance of our Symphony tCGM System with Prelude as the new skin permeation element," stated Patrick T. Mooney, M.D., Echo's Chairman and Chief Executive Officer. "We are very excited about our significant development progress thus far, and we look forward to making additional progress with Symphony throughout 2008."

Echo's pilot clinical study will enroll ten (10) patients with diabetes (either Type 1 or Type 2) and will compare data obtained from its Symphony tCGM System with both the "gold standard" YSI Glucose Analyzer and a widely-used, commercially available "finger-stick" glucometer. The study will collect more than 900 data pairs to be used in the analyses. Reference glucose measurements will be made at 15 minute intervals for 24 hours with the study data blinded to study subjects and study personnel.

About Echo Therapeutics

Echo Therapeutics is focused on medical devices and specialty pharmaceuticals. Echo is developing a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system for patients with diabetes and for use in hospital critical care units, together with a wide range of novel topical reformulations of widely-used, FDA-approved products.

Cautionary Statement Regarding Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward- looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies regarding the efficacy of Echo's Symphony tCGM System, the failure of future development and preliminary marketing efforts related to Echo's tCGM systems, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic products based on its skin permeation platform technologies, including the Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, and regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its tCGM systems. Furthermore, Echo's tCGM system has not yet been approved for sale. The regulatory approval process for its tCGM system involves, among other factors, successfully completing pilot and pivotal clinical trials and obtaining a premarket approval, or PMA, from the FDA. The PMA process requires Echo to prove the safety and efficacy of its tCGM system to the FDA's satisfaction. This process can be expensive and uncertain, and there is no guarantee that Echo will be able to submit a PMA for its Symphony tCGM System or that its Symphony tCGM System will be approved by the FDA in any specific timeframe or at all. In addition, clinical testing of Echo's products and eventual commercialization of its products are subject to all of the risks and uncertainties set forth in its periodic reports filed with the Securities and Exchange Commission.

These and other factors are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-KSB for the year ended December 31, 2007, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. The foregoing list of factors is not exhaustive. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:

Patrick T. Mooney, M.D. Lilian Stern

Chairman and Chief Executive Officer Stern Investor Relations

(856) 429-8778 (212) 362-1200


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Silence Therapeutics Announces Board Changes
2. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
3. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
4. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
5. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
6. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
7. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
8. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
9. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
10. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
11. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... England , December 5, 2016 ... Transitions to Deputy Chairman   ... on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative ... has been appointed as non-executive Chairman, effective January 1 st ... of Mission Therapeutics as a non-executive Director in July 2015. ...
(Date:12/4/2016)... -- Former Attorney General of Louisiana , ... law firm of Kahn Swick & Foti, LLC ("KSF"), announces ... (NYSE: LCI ). On November ... Charges in Generic-Drug Probe to Be Filed by Year-End," which ... about two years ago, now spans more than a dozen ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 ... evaluating efficacy and safety of CTL019, an investigational ... in relapsed/refractory (r/r) pediatric and young adult patients ... presented today during an oral session at the ... (Abstract #221, December 3, 4:00-5:30 p.m.). The global ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 04, 2016 , ... ... have new attractive animation styles with unique displacement design elements," said Christina Austin ... lower third designs. Choose from a variety of design styles that include both ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges on regular brushing of ... optimal results. This important necessity inspired an inventor from Las Vegas, Nev., to design ... that people break or avoid bad techniques of brushing the teeth in order to ...
(Date:12/2/2016)... ... , ... Two years ago, Arizona State University students produced ... 1 million viewers and won numerous honors, including the region’s top Emmy and ... Cronkite School of Journalism and Mass Communication are following up their award-winning investigation ...
(Date:12/2/2016)... ... December 02, 2016 , ... More ... in Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, ... funds for area students and operating support to UNCF-member institutions, including Miles College, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and Related Disorders (CARD) ... by autism spectrum disorder (ASD) and other developmental disabilities. The group, which is being ... and other caregivers the opportunity to share stories and advice, seek help, and continue ...
Breaking Medicine News(10 mins):